Minervate Showcases AI-Powered Clinical Trials Platform and Regulatory Excellence at Web Summit 2025

Minervate Ltd., a London-based healthtech and regulatory compliance company, will be spotlighted at Web Summit 2025 as an Impact StartUp, recognized for its contribution to ethical, AI-enabled transformation in clinical trials and pharmaceutical compliance.

With a foundation built on GxP excellence, innovation, and diversity, Minervate continues to redefine how pharmaceutical, biotech, and clinical research organizations accelerate drug development-ensuring quality, safety, and accessibility for patients worldwide.
"Minervate stands for innovation with integrity," said Lola Enape, Founder and CEO of Minervate. "Our mission is to harmonize technology and compliance so that every scientific advancement is both ethical and impactful. At Web Summit, we're proud to show how AI can empower life sciences organizations to move faster without compromising quality."

Driving Excellence in GxP Compliance and Innovation
Founded in 2017, Minervate has established itself as a globally trusted partner in GxP compliance and regulatory technology. The company provides bespoke regulatory, quality, and digital compliance solutions aligned with international standards including MHRA, FDA, EMA, Health Canada, and ANVISA.

Minervate's areas of expertise include:
• Regulatory & GxP Expertise: Comprehensive compliance documentation, risk-based auditing, inspection readiness, SOP development, and CAPA management.
• Quality Assurance for Clinical Trials: Ethical protocol adherence, audit readiness, and data integrity across global studies.
• Technological Innovation: Deployment of AI-enabled, compliance-grade clinical trial data platforms for flexible, remote, and on-site management.
• Diversity in Scientific Leadership: A woman-led organization driven by a diverse team of subject matter experts and advocates for inclusion in life sciences.
• Patient-Centric Mission: Ensuring faster, safer, and more inclusive delivery of life-saving therapies.
Showcasing at Web Summit 2025
At Web Summit 2025, Minervate will present its AI-enabled, compliance-grade clinical trials data SaaS platform - a next-generation solution designed to:
• Accelerate drug discovery by analyzing clinical and scientific data at scale.
• Ensure safety, quality, and compliance across the trial lifecycle.
• Integrate eCRF, eConsent, and data management tools to improve efficiency and patient outcomes.

The platform enables sponsors, CROs, and biotech companies to automate GxP documentation, manage global multi-site trials, and generate real-time insights that reduce time-to-market for new therapies.
Key Highlights for Media
🧠 Innovation in HealthTech:
Proprietary AI algorithms enhance decision-making, streamline workflows, and uphold ethical standards across trials.

🌍 Real-World Impact:
Trusted by global pharmaceutical leaders for implementing advanced quality systems and audit programs.

👩🏽‍🔬 Diverse Leadership:
Led by FemTech champion Lola Enape, Minervate's leadership brings over 25 years of combined expertise in clinical operations, data analytics, and regulatory affairs.

🏆 Recognized Excellence:
Honored as a Web Summit 2025 Impact StartUp for pioneering innovation in ethical AI and clinical data transformation.

Minervate Sales and Marketing Team
📧 sales@minervate.co.uk
🌐 www.minervate.co.uk
🏢 128 City Road, London, EC1V 2NX, United Kingdom

About Minervate
Minervate Ltd. is a London-based healthtech company empowering pharmaceutical, biotech, and clinical research organizations to optimize drug development through AI-enabled, compliance-grade clinical trials data SaaS platforms and GxP systems. The company bridges innovation and integrity, ensuring that technological progress translates into safe, high-quality, and accessible therapies.

Fast Facts
Founded: 2017
Headquarters: London, United Kingdom
Industry: Healthtech / Clinical Research / AI
Website: www.minervate.co.uk
LinkedIn: linkedin.com/company/minervate

This release was published on openPR.